*Sponsored
Gary Silver of Market Crux Announces MAIA Biotechnology (NYSE: MAIA) As His Next Potential Breakout Idea Starting This Morning—Thursday, June 5, 2025
And Here's Why He's Got (MAIA) Pulled Up Right Now….
Analyst Target: Noble Capital Markets' Robert LeBoyer Assigned A $14 Target On (MAIA), Suggesting Over 695% Upside Potential From Recent Levels.
Recent Momentum Move: (MAIA) Moved Approximately 95% In Under A Month, From $1.40 To $2.74 Between April And May.
Trials Set To Expand: (MAIA) Plans To Launch A Phase 3 And Three Phase 2 Trials Targeting Major Tumors By Mid-2025.
Check Out (MAIA)While It's Still Early… June 5, 2025 Dear Reader,
Every once in a while, a company quietly steps into a space where few—if any—have ventured. That's what's happening with MAIA Biotechnology (NYSE: MAIA), which is now advancing what appears to be the only telomere-targeting agent currently moving through clinical development. The compound, now formally named Ateganosine (THIO), isn't just another candidate—it represents a unique scientific pathway that could reshape how late-stage cancers are approached. And the momentum behind it is beginning to show. In less than a month, (MAIA) moved approximately 95%—from $1.40 in April to $2.74 in May. At the same time, we discovered analyst Robert LeBoyer of Noble Capital Markets has placed a $14 target on the company, reflecting what could be over 695% upside from current levels. 
See What's Pushing (MAIA) to the Top of Our Watchlist for Thursday, June 5, 2025
New survival data from (MAIA)'s Phase 2 THIO-101 trial is raising eyebrows—showing a median overall survival of 16.9 months in NSCLC patients who had exhausted both checkpoint inhibitors and chemotherapy. That's nearly triple the 5–6 month outcome typically seen with standard chemo—and the latest projections now suggest a 99% chance Ateganosine beats that benchmark outright. Earlier trial data also pointed to a possible 17.8-month median survival—offering further evidence of consistency. Across the board, the results hint at one thing: potential staying power in some of the most advanced cancer cases. And with a pipeline that extends far beyond NSCLC, (MAIA)'s clinical momentum may just be getting started. (MAIA) has secured three FDA Orphan Designations for liver, lung, and brain cancers—alongside a Rare Pediatric Disease Designation that may qualify it for a priority review voucher upon approval, a pathway known for drawing industry-wide attention. 
Adding to its regulatory progress, the USAN Council officially approved "Ateganosine" as the nonproprietary name for THIO, marking a key advancement in the compound's development and recognition. Early Results Show Full Tumor Response—Now (MAIA) Is Moving Into Phase 3
At the heart of (MAIA)'s approach is a dual-action immunotherapy strategy. Ateganosine targets telomeres directly—cutting off the survival mechanism of cancer cells—and then triggers a downstream immune response when followed by checkpoint inhibitors such as Libtayo® or tislelizumab. In preclinical studies, this sequence resulted in 60% complete response in lung cancer models and 100% complete response in colorectal cancer models. In both cases, animals rechallenged with large volumes of cancer cells saw no recurrence, indicating a strong immune memory effect. This science is now expanding into clinical trials across additional tumor types. A new Phase 3 trial (THIO-104) in NSCLC is expected to begin enrollment mid-2025. This pivotal trial is designed to act as either a confirmatory or full approval study depending on THIO-101's regulatory outcome. Simultaneously, three more Phase 2 trials are planned to explore Ateganosine's application in colorectal, liver, and small cell lung cancers. What's Happening Behind the Curtain
In the March 2025 Letter to Shareholders, CEO Dr. Vlad Vitoc outlined a focused approach built around long-term exclusivity, scientific durability, and deliberate pipeline growth. Thanks to its rare designations, (MAIA) stands to benefit from up to 7 years of exclusivity in the U.S. and up to 10 years in key international markets. Adding to this foundation, (MAIA) secured a clinical supply partnership with global oncology powerhouse BeiGene—supporting trial combinations of Ateganosine with checkpoint inhibitors in complex cancers such as small cell lung and hepatocellular carcinoma. At the scientific helm, Chief Scientific Officer Dr. Sergei Gryaznov—co-inventor of Ateganosine—continues to guide the innovation forward, drawing from his decades of expertise in telomere biology and translational cancer research. All Eyes on 2026: (MAIA)'s Phase 3 Could Set the Stage for Early Regulatory Review
Enrollment for the pivotal THIO-104 Phase 3 trial is expected to begin shortly, with interim findings potentially supporting an early approval submission as soon as 2026. At the same time, the expanded THIO-101 study has entered Part C, with new patients now being dosed. Looking ahead, (MAIA) expects to initiate enrollment for three additional Phase 2 trials—targeting colorectal, liver, and small cell lung cancers—by year-end. As the only known company currently pushing a telomere-targeting anticancer agent through clinical development, (MAIA) continues to hold a unique position in the field—both in terms of scientific direction and clinical strategy. (MAIA) Just Entered the Spotlight
While (MAIA) may not yet be a household name, momentum tends to build quickly when data begins to speak for itself. Backed by a focused development plan, long-term regulatory protection, and a mechanism that addresses both tumor survival and immune activation, (MAIA) is showing signs of something worth watching closely. Expect more updates as this program continues to advance. 7 Reasons Why (MAIA) Just Hit Our Radar This Morning—Thursday,
June 5, 2025
1. High Confidence Coverage: Noble Capital Markets' Robert LeBoyer has placed a $14 target on (MAIA), suggesting over 695% upside from recent ranges. 2. Recent Momentum Move: (MAIA) moved approximately 95% in under a month—from $1.40 on April 10 to $2.74 on May 2, 2025. 3. Unmatched Scientific Focus: (MAIA) appears to be the only company advancing a telomere-targeting anticancer agent through clinical trials. 4. Unexpected Survival Strength: (MAIA)'s Phase 2 data in NSCLC shows 16.9 months median survival—triple the typical 5–6 month outcome with chemotherapy. 5. Regulatory Rarity Advantage: With three Orphan and one Rare Pediatric Disease Designation, (MAIA) could benefit from long-term exclusivity protections. 6. Preclinical Powerhouse: Lung and colorectal models showed full response and immune memory effects after exposure to (MAIA)'s lead candidate. 7. Pipeline Expansion Imminent: A pivotal Phase 3 trial and three more Phase 2 studies are scheduled to begin mid-2025 targeting key tumor types. Check Out (MAIA)While It's Still Early…
With an approximate 95% move in under a month, a $14 analyst target suggesting significant upside from current levels, and what appears to be the only telomere-targeting anticancer agent in clinical development, MAIA Biotechnology (NYSE: MAIA) is now commanding closer attention. Add in standout survival data, multiple FDA designations, and a rapidly advancing clinical program—and it's easy to see why this one is starting to turn heads. (MAIA) is front and center right now. With momentum picking up, the earlier the look, the better. Also—please keep a lookout for my next update—it could be out at any moment Sincerely, Gary Silver
Managing Editor, MarketCrux
| 
